media – Page 28 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Nearly 2 billion US dollars! What sparks can be ignited between CSPC and AstraZeneca?

Lung cancer product Axitinib In the field of lung cancer treatment, CSPC has achieved outstanding results in the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations (EGFR ex20ins) by combining humanized EGFR monoclonal antibodies with AstraZeneca’s heavyweight product, Axitinib. The relevant research data was published in Nature Communication and has been widely recognized by the international academic community. At present, the key phase II single arm study for this indication is also being carried out smoothly, and good clinical research data has been obtained. It will be applied for market as soon as possible. Based on this good cooperation result, representatives from both parties signed a cooperation agreement in order to continue the collaboration in the Phase III confirmatory study of this indication. Chen Kangwei, General Manager of AstraZeneca China Oncology Division, stated that the strategic cooperation between the two parties is through a strong alliance ...
- Source: drugdu
- 89
- October 10, 2024
Latest! AstraZeneca announces 10 billion yuan cooperation

On October 7, AstraZeneca and CSPC Pharmaceutical Group signed an exclusive licensing agreement, and AstraZeneca will obtain CSPC Pharmaceutical Group’s preclinical candidate small molecule drug YS2302018. The transaction amount hit a new high. According to the agreement, CSPC Pharmaceutical Group will receive an advance payment of US$100 million and is entitled to receive potential development milestone payments of up to US$370 million and potential sales milestone payments of up to US$1.55 billion, as well as tiered sales commissions calculated based on the annual net sales of the product (the total transaction amount exceeds RMB 10 billion at the current exchange rate). YS2302018 is a preclinical innovative small molecule lipoprotein (a) (Lp(a)) inhibitor used to develop new lipid-lowering therapies, as well as monotherapy or combination therapy for a variety of cardiovascular diseases, including in combination with the oral small molecule PCSK9 inhibitor AZD0780. Lpa is an important target in the field ...
- Source: drugdu
- 79
- October 10, 2024
Domestic substitution has entered the sprint period, where is the key?

As one of the hottest terms in 2024, “new quality productivity” is not only an upgrade of economic terms, but also a reflection of the process of era change, hiding the pulse of future industrial development. In many reports and documents issued by the state this year, the field of life sciences is closely linked to new quality productivity. At present, Beijing, Shanghai, Guangdong, Chongqing, Zhejiang, Jiangsu and other provinces and cities have successively issued documents to promote the development of new quality productivity and detailed implementation. At present, the field of life sciences is in a period of rapid change, showing unprecedented vitality. After returning to China after studying abroad, many outstanding scholars have greatly promoted the development of this field, especially the development of basic medical research, biotechnology innovation, biopharmaceuticals, clinical diagnosis and treatment. The development is particularly prosperous. Although the medical industry is treacherous, the rules are ...
- Source: drugdu
- 63
- October 10, 2024
Let’s go to Europe to seek gold

It is a general trend for pharmaceutical companies to go overseas, and the proposition of the times behind it is also advancing with the times. Under the new changes, how to re-examine the gold-mining places such as the United States, Europe, and Southeast Asia? Different countries and regions have different market sizes and policies and regulations. How to examine the pros and cons of the market and formulate a more suitable strategy for going overseas? Everything needs to be answered by the industry. At present, more and more signs show that pharmaceutical companies are no longer just focusing on the “fat meat” of the US market as in the past, and countries and regions such as Europe are becoming more and more important. After being hit repeatedly by the FDA, more and more PD-1s have moved to Europe and been approved for listing. Since the beginning of this year, domestic ...
- Source: drugdu
- 75
- October 10, 2024
Vietnam Medipharm Expo

Organiser：Ministry of Health of Vietnam Time：July 31 – August 2, 2025 Address：799 Đ. Nguyễn Văn Linh, Tân Phú, Quận 7, Hồ Chí Minh, Vietnam Exhibition hall：Saigon Exhibition and Convention Center (SECC) Product range: Medical Products: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical health products and equipment, medical institution and laboratory technology equipment, medical information and technology exchange, beauty instruments Analytical Instruments: Optical analysis instruments, mass spectrometers, spectrographs, chromatographs, spectroscopes, frequency spectrum analyzers, electrochemical analysis instruments, ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, various portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, component analysis instruments, syringe analysis instruments, and other general analytical instruments Laboratory Equipment: Laboratory instruments and equipment, laboratory automation and accessories, optical equipment, microscopes, optical ...
- Source: drugdu
- 96
- October 10, 2024
Merger of two well-known pharmaceutical companies

On October 7, Jiahe Bio announced that it would acquire Yitong Pharmaceuticals by merger. The name of the merged company will be changed to Yitong Jiahe Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Yitong Jiahe”). The transaction is carried out in the form of a share swap. The price of the proposed merger will be fully settled by issuing consideration shares. After the merger is completed, the shareholders of both parties will jointly hold the equity of Yitong Jiahe, and Jiahe Bio will not have any cash expenditure. According to the listing rules, the transaction constitutes a reverse acquisition of Jiahe Bio. In the merged Yitong Jiahe, the original Yitong Pharmaceutical shareholders accounted for 77.43%, and the original Jiahe Bio shareholders accounted for 22.57%. The actual controller of Yitong Pharmaceutical will become the controlling shareholder of Yitong Jiahe. Based on the rules of Chapter 18A of the Hong Kong ...
- Source: drugdu
- 68
- October 10, 2024
PCSK9 antibody marketing application received notification

On September 29, 2024, two acceptance numbers for Junshi Biosciences’s PCSK9 antibody marketing application were notified, indicating that they have not been approved (possibly due to voluntary withdrawal or pending approval). In April 2023, Junshi Biosciences received 4 acceptance numbers for its PCSK9 antibody market application, of which 2 were notified this time, and the other 2 have not yet received results. Four acceptance numbers involve two specifications (pre filled syringes, pre filled automatic syringes) and two indications. This two notifications indicate that a certain specification or indication has not been approved. The competition for PCSK9 targets is particularly fierce. In addition to antibodies from Amgen and Sanofi, PCSK9 antibodies from Sinovac Biotech and PCSK9 siRNA from Novartis have already been approved for marketing. Among them, Novartis’ PCSK9 siRNA only needs to be administered once every six months. For this target, there are more differentiated products under development, including Merck’s ...
- Source: drugdu
- 72
- October 9, 2024
The 2024 “Most Promising New Talent in Biopharmaceuticals” list has been released!

Recently, well-known industry media Endpoint News released the “Biopharma’s Most Exciting Startups in 2024” list, which includes 11 biotechnology companies. These emerging research fields include gene editing, immunotherapy, antibody conjugated drugs (ADCs), weight loss therapy, and multiple other directions. This article will introduce these 11 rising stars (listed in no particular order) to readers, based on this ranking and official information from various companies. Lifordi Immunotherapies is a biotechnology company dedicated to developing ADC therapies for the treatment of autoimmune and inflammatory diseases. Lifordi was founded in 2023 and has secured $70 million in Series A funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture, with the goal of advancing the main candidate drug LFD-200 into clinical trials and obtaining preliminary data by the end of 2025. Lifordi’s main ADC therapy LFD-200 targets myeloid cells and lymphocytes by targeting highly internalized cell surface facial mask proteins. This therapy has ...
- Source: drugdu
- 93
- October 9, 2024
Cardiovascular device giant, official announcement of split

Recently, Integer Holdings Corporation, the world’s largest CDMO company with deep roots in cardiovascular devices, announced that it will divest its non-medical business. The company has reached an agreement to sell its Electrochem business, which focuses on the energy, military and environmental fields, to Ultralife Corporation for $50 million in cash, and the transaction is expected to be completed by the end of October. Joe Dziedzic, president and CEO of Integer, said that after the transaction is completed, Integer will be a pure medical company with additional cash to repay debt and execute our inorganic growth strategy. Ultralife is an ideal buyer for Electrochem because they are a leader in providing critical power solutions to a variety of industries including energy, defense and environmental markets. As a global medical device CDMO leader, Integer’s medical customers include large multinational medical device OEMs and their subsidiaries, including Abbott, Johnson & Johnson, Boston ...
- Source: drugdu
- 69
- October 9, 2024
The National Medical Insurance Administration responded to the next direction of the centralized procurement of consumables

Recently, the National Medical Insurance Administration issued the “Reply of the National Medical Insurance Administration to Suggestion No. 2090 of the Second Session of the Fourteenth National People’s Congress” (hereinafter referred to as the “Reply”). In the “Reply”, the National Medical Insurance Administration explained the next steps for the centralized procurement of consumables and the implementation of innovative medical devices. In particular, the next steps for local centralized procurement were explained. The “Reply” pointed out that centralized procurement is still in the stage of reform and overcoming difficulties. The National Medical Insurance Administration will further supervise and improve the rules of local centralized procurement, improve the scientificity and standardization of local centralized procurement, and improve the quality and efficiency of procurement. First, expand the scope of the alliance and strengthen national coordination. Encourage local governments to carry out alliance procurement, and upgrade to national alliance procurement if conditions are met. ...
- Source: drugdu
- 71
- October 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.